A Mobile Health App to Improve HIV Medication Adherence: Protocol for a Pilot Randomized Controlled Trial

Susan Ramsey, Evan Ames, Julia Uber, Samia Habib, Seth Clark, Susan Ramsey, Evan Ames, Julia Uber, Samia Habib, Seth Clark

Abstract

Background: Adherence to antiretroviral therapy (ART) is essential for allowing persons living with HIV to live longer, healthier lives. However, a large portion of this population has suboptimal adherence and are not virally suppressed. Conventional interventions aimed at improving ART adherence lack portability and scalability, and improvements in adherence are not often sustained. Mobile health (mHealth) ART interventions offer a low-cost and accessible method of improving adherence, but many have limited functionality and do not offer comprehensive support. The combination of an mHealth intervention with a face-to-face adherence intervention and interactive health coaching feature may offer sufficient support in a manner that is sensitive to resource limitations that are often found in HIV treatment settings. This paper details the protocol of a study designed to evaluate the potential of an enhanced mHealth intervention for improving ART adherence.

Objective: The primary objective of this study is to assess the feasibility and acceptability of the Fitbit Plus app enhanced with a face-to-face LifeSteps session (Fitbit Plus condition) for improving ART adherence. In addition, we will determine the preliminary efficacy of the intervention by calculating treatment effect sizes.

Methods: This study will be conducted in 2 phases. The intervention will be developed and piloted with a small group of participants during phase 1. Pilot participants will provide feedback that will be used to refine the intervention for phase 2. In phase 2, a preliminary randomized controlled trial (RCT) comparing Fitbit Plus with a condition that approximates the standard of care (SOC) will be conducted with 60 persons living with HIV. Interviews will be conducted with RCT participants at baseline, and follow-up interviews will be conducted at 1, 3, 6, and 12 months. ART adherence is the primary outcome and will be monitored throughout the study via electronic pill boxes. Effect sizes will be generated using a fractional logit model estimated by generalized estimating equations.

Results: Phase 1 of this trial is complete; data collection for phase 2 is ongoing. Follow-ups with enrolled participants will conclude in January 2020.

Conclusions: This study will contribute to the literature on ART adherence and may produce an efficacious intervention. Owing to a small sample size, there may be insufficient power to detect statistically significant differences between Fitbit Plus and SOC. However, if Fitbit Plus is found to be acceptable and feasible and yields promising effect size estimates, this pilot study could serve as the foundation for a larger, fully powered trial of Fitbit Plus.

Trial registration: ClinicalTrials.gov NCT02676128; https://ichgcp.net/clinical-trials-registry/NCT02676128.

International registered report identifier (irrid): DERR1-10.2196/15356.

Keywords: HIV; medication adherence; mobile health.

Conflict of interest statement

Conflicts of Interest: SR has an investigator-sponsored research agreement with Gilead Sciences, Inc, for the provision of medication for another trial.

©Susan Ramsey, Evan Ames, Julia Uber, Samia Habib, Seth Clark. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 13.11.2019.

References

    1. Centers for Disease Control and Prevention. 2019. [2019-10-07]. Estimated HIV Incidence and Prevalence in the United States 2010–2016 .
    1. Centers for Disease Control and Prevention. 2018. [2019-10-07]. Diagnoses of HIV Infection in the United States and Dependent Areas, 2017 .
    1. Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust. 2007 Feb 5;186(3):146–51. doi: 10.5694/j.1326-5377.2007.tb00839.x.
    1. Antiretroviral Therapy Cohort Collaboration Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008 Jul 26;372(9635):293–9. doi: 10.1016/S0140-6736(08)61113-7.
    1. Centers for Disease Control and Prevention. 2018. [2019-10-07]. Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data United States and 6 Dependent Areas, 2016 .
    1. Ortego C, Huedo-Medina TB, Llorca J, Sevilla L, Santos P, Rodríguez E, Warren MR, Vejo J. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011 Oct;15(7):1381–96. doi: 10.1007/s10461-011-9942-x.
    1. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000 Jul 4;133(1):21–30. doi: 10.7326/0003-4819-133-1-200007040-00004.
    1. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, Moss A. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001 Jun 15;15(9):1181–3. doi: 10.1097/00002030-200106150-00015.
    1. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, Montaner JS. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):529–36. doi: 10.1097/QAI.0b013e31819675e9.
    1. Simoni JM, Amico KR, Smith L, Nelson K. Antiretroviral adherence interventions: translating research findings to the real world clinic. Curr HIV/AIDS Rep. 2010 Feb;7(1):44–51. doi: 10.1007/s11904-009-0037-5.
    1. Safren SA, Otto MW, Worth J. Life-steps: applying cognitive behavioral therapy to HIV medication adherence. Cogn Behav Pract. 1999 Sep;6(4):332–41. doi: 10.1016/S1077-7229(99)80052-2.
    1. Safren SA, Otto MW, Worth JL, Salomon E, Johnson W, Mayer K, Boswell S. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther. 2001 Oct;39(10):1151–62. doi: 10.1016/s0005-7967(00)00091-7.
    1. Fisher JD, Fisher WA, Amico KR, Harman JJ. An information-motivation-behavioral skills model of adherence to antiretroviral therapy. Health Psychol. 2006 Jul;25(4):462–73. doi: 10.1037/0278-6133.25.4.462.
    1. Safren SA, O'Cleirigh C, Tan JY, Raminani SR, Reilly LC, Otto MW, Mayer KH. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009 Jan;28(1):1–10. doi: 10.1037/a0012715.
    1. Safren SA, O'Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012 Jun;80(3):404–15. doi: 10.1037/a0028208.
    1. Finitsis DJ, Pellowski JA, Johnson BT. Text message intervention designs to promote adherence to antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. PLoS One. 2014;9(2):e88166. doi: 10.1371/journal.pone.0088166.
    1. Cooper V, Clatworthy J, Whetham J, Consortium E. mHealth interventions to support self-management in HIV: a systematic review. Open AIDS J. 2017;11:119–32. doi: 10.2174/1874613601711010119.
    1. Muessig KE, Pike EC, Legrand S, Hightow-Weidman LB. Mobile phone applications for the care and prevention of HIV and other sexually transmitted diseases: a review. J Med Internet Res. 2013 Jan 4;15(1):e1. doi: 10.2196/jmir.2301.
    1. Chaiyachati KH, Ogbuoji O, Price M, Suthar AB, Negussie EK, Bärnighausen T. Interventions to improve adherence to antiretroviral therapy: a rapid systematic review. AIDS. 2014 Mar;28(Suppl 2):S187–204. doi: 10.1097/QAD.0000000000000252.
    1. Amico KR, Orrell C. Antiretroviral therapy adherence support: recommendations and future directions. J Int Assoc Provid AIDS Care. 2013;12(2):128–37. doi: 10.1177/1545109712459041.
    1. Sandelowski M, Voils CI, Chang Y, Lee E. A systematic review comparing antiretroviral adherence descriptive and intervention studies conducted in the USA. AIDS Care. 2009 Aug;21(8):953–66. doi: 10.1080/09540120802626212.
    1. Wolever RQ, Simmons LA, Sforzo GA, Dill D, Kaye M, Bechard EM, Southard ME, Kennedy M, Vosloo J, Yang N. A systematic review of the literature on health and wellness coaching: defining a key behavioral intervention in healthcare. Glob Adv Health Med. 2013 Jul;2(4):38–57. doi: 10.7453/gahmj.2013.042.
    1. Hill B, Richardson B, Skouteris H. Do we know how to design effective health coaching interventions: a systematic review of the state of the literature. Am J Health Promot. 2015;29(5):e158–68. doi: 10.4278/ajhp.130510-LIT-238.
    1. Kivelä K, Elo S, Kyngäs H, Kääriäinen M. The effects of health coaching on adult patients with chronic diseases: a systematic review. Patient Educ Couns. 2014 Nov;97(2):147–57. doi: 10.1016/j.pec.2014.07.026.
    1. Perera AI, Thomas MG, Moore JO, Faasse K, Petrie KJ. Effect of a smartphone application incorporating personalized health-related imagery on adherence to antiretroviral therapy: a randomized clinical trial. AIDS Patient Care STDS. 2014 Nov;28(11):579–86. doi: 10.1089/apc.2014.0156.
    1. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002 Jan 25;16(2):269–77. doi: 10.1097/00002030-200201250-00017.
    1. Jeste DV, Palmer BW, Appelbaum PS, Golshan S, Glorioso D, Dunn LB, Kim K, Meeks T, Kraemer HC. A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry. 2007 Aug;64(8):966–74. doi: 10.1001/archpsyc.64.8.966.
    1. First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition. New York: New York State Psychiatric Institute; 1997.
    1. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006 Dec 1;43(Suppl 1):S23–35. doi: 10.1097/01.qai.0000248342.05438.52.
    1. Nielsen. 2016. [2017-12-27]. Millennials Are Top Smartphone Users .
    1. Sabin LL, DeSilva MB, Hamer DH, Xu K, Zhang J, Li T, Wilson IB, Gill CJ. Using electronic drug monitor feedback to improve adherence to antiretroviral therapy among HIV-positive patients in China. AIDS Behav. 2010 Jun;14(3):580–9. doi: 10.1007/s10461-009-9615-1.
    1. Krummenacher I, Cavassini M, Bugnon O, Schneider MP. An interdisciplinary HIV-adherence program combining motivational interviewing and electronic antiretroviral drug monitoring. AIDS Care. 2011 May;23(5):550–61. doi: 10.1080/09540121.2010.525613.
    1. Stout R, Wirtz P, Carbonari J, Boca Fk. Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol Suppl. 1994 Dec;12:70–5. doi: 10.15288/jsas.1994.s12.70.
    1. Sobell L, Sobell M. Timeline Followback User's Guide: A Calendar Method for Assessing Alcohol and Drug Use. Toronto, Ontario, Canada: Addiction Research Foundation; 1996.
    1. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401. doi: 10.1177/014662167700100306.
    1. Bova CA, Fennie KP, Knafl GJ, Dieckhaus KD, Watrous E, Williams AB. Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. AIDS Behav. 2005 Mar;9(1):103–10. doi: 10.1007/s10461-005-1685-0.
    1. Deschamps AE, de Geest S, Vandamme A, Bobbaers H, Peetermans WE, van Wijngaerden E. Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care STDS. 2008 Sep;22(9):735–43. doi: 10.1089/apc.2007.0229.
    1. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000 Apr 1;59(1):17–31. doi: 10.1016/s0376-8716(99)00104-0.
    1. Raiff B, Jarvis B, Dallery J. Text-message reminders plus incentives increase adherence to antidiabetic medication in adults with type 2 diabetes. J Appl Behav Anal. 2016 Dec;49(4):947–53. doi: 10.1002/jaba.337.
    1. Blashill AJ, Bedoya CA, Mayer KH, O'Cleirigh C, Pinkston MM, Remmert JE, Mimiaga MJ, Safren SA. Psychosocial syndemics are additively associated with worse art adherence in HIV-infected individuals. AIDS Behav. 2015 Jun;19(6):981–6. doi: 10.1007/s10461-014-0925-6.
    1. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG) AIDS Care. 2000 Jun;12(3):255–66. doi: 10.1080/09540120050042891.
    1. Wilson IB, Lee Y, Michaud J, Fowler FJ, Rogers WH. Validation of a new three-item self-report measure for medication adherence. AIDS Behav. 2016 Nov;20(11):2700–8. doi: 10.1007/s10461-016-1406-x.
    1. The LifeWindows Project Team. The LifeWindows Information Motivation Behavioral Skills ART Adherence Questionnaire (LW-IMB-AAQ) University of Connecticut: Center for Health, Intervention, and Prevention. 2006
    1. Johnson MO, Neilands TB, Dilworth SE, Morin SF, Remien RH, Chesney MA. The role of self-efficacy in HIV treatment adherence: validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES) J Behav Med. 2007 Oct;30(5):359–70. doi: 10.1007/s10865-007-9118-3.
    1. Blashill AJ, Perry N, Safren SA. Mental health: a focus on stress, coping, and mental illness as it relates to treatment retention, adherence, and other health outcomes. Curr HIV/AIDS Rep. 2011 Dec;8(4):215–22. doi: 10.1007/s11904-011-0089-1.
    1. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):181–7. doi: 10.1097/QAI.0b013e31822d490a.
    1. Gonzalez A, Barinas J, O'Cleirigh C. Substance use: impact on adherence and HIV medical treatment. Curr HIV/AIDS Rep. 2011 Dec;8(4):223–34. doi: 10.1007/s11904-011-0093-5.
    1. Sobell LC, Sobell MB. Validity of self-reports in three populations of alcoholics. J Consult Clin Psychol. 1978 Oct;46(5):901–7. doi: 10.1037//0022-006x.46.5.901.
    1. Sobell LC, Sobell MB. Convergent validity: an approach to increasing confidence in treatment outcome conclusions with alcohol and drug abusers. In: Sobell LC, Sobell MB, Ward E, editors. Evaluating Alcohol and Drug Abuse Treatment Effectiveness: Recent Advances. New York: Pergamon Press; 1980.
    1. Sobell L, Maisto S, Sobell M, Cooper A. Reliability of alcohol abusers' self-reports of drinking behavior. Behav Res Ther. 1979;17(2):157–60. doi: 10.1016/0005-7967(79)90025-1.
    1. Lewinsohn PM, Seeley JR, Roberts RE, Allen NB. Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging. 1997 Jun;12(2):277–87. doi: 10.1037//0882-7974.12.2.277.
    1. O'Cleirigh C, Valentine SE, Pinkston M, Herman D, Bedoya CA, Gordon JR, Safren SA. The unique challenges facing HIV-positive patients who smoke cigarettes: HIV viremia, ART adherence, engagement in HIV care, and concurrent substance use. AIDS Behav. 2015 Jan;19(1):178–85. doi: 10.1007/s10461-014-0762-7.
    1. Shuter J, Bernstein S. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. Nicotine Tob Res. 2008 Apr;10(4):731–6. doi: 10.1080/14622200801908190.
    1. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991 Sep;86(9):1119–27. doi: 10.1111/j.1360-0443.1991.tb01879.x.
    1. McLellan AT, Alterman AI, Cacciola J, Metzger D, O'Brien CP. A new measure of substance abuse treatment. Initial studies of the treatment services review. J Nerv Ment Dis. 1992 Feb;180(2):101–10. doi: 10.1097/00005053-199202000-00007.
    1. Papke LE, Wooldridge JM. Panel data methods for fractional response variables with an application to test pass rates. J Econ. 2008;145(1-2):121–33. doi: 10.1016/j.jeconom.2008.05.009.
    1. Hall SM, Delucchi KL, Velicer WF, Kahler CW, Ranger-Moore J, Hedeker D, Tsoh JY, Niaura R. Statistical analysis of randomized trials in tobacco treatment: longitudinal designs with dichotomous outcome. Nicotine Tob Res. 2001 Aug;3(3):193–202. doi: 10.1080/14622200110050411.
    1. Liang K, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13–22. doi: 10.2307/2336267.
    1. Zeger SL, Liang K. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986 Mar;42(1):121–30. doi: 10.2307/2531248.
    1. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986 Dec;51(6):1173–82. doi: 10.1037//0022-3514.51.6.1173.
    1. Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology. 1992 Mar;3(2):143–55. doi: 10.1097/00001648-199203000-00013.
    1. Pearl J. Causality: Models, Reasoning, and Inference. Cambridge, UK: Cambridge University Press; 2000.
    1. UNICEF . For Every Child, End AIDS: Seventh Stocktaking Report, 2016. New York, NY: UNICEF; 2016.
    1. Fisher JD, Amico KR, Fisher WA, Harman JJ. The information-motivation-behavioral skills model of antiretroviral adherence and its applications. Curr HIV/AIDS Rep. 2008 Nov;5(4):193–203. doi: 10.1007/s11904-008-0028-y.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다